Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Reports Fiscal Year 2023 Financial Results and Operational Highlights

GlobeNewswire June 27, 2023

Medicenna Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

GlobeNewswire April 27, 2023

Medicenna to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 18, 2023

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

GlobeNewswire April 17, 2023

Medicenna Provides Clinical Update from Monotherapy Dose Escalation Portion of Phase 1/2 ABILITY Study

GlobeNewswire March 30, 2023

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

GlobeNewswire March 15, 2023

Medicenna to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 2, 2023

Medicenna Establishes At-the-Market Sales Facility

GlobeNewswire February 17, 2023

Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire February 7, 2023

Medicenna to Present at the 2023 Guggenheim Oncology Conference

GlobeNewswire January 31, 2023

Medicenna to Announce Third Quarter Fiscal 2023 Financial Results and Operational Highlights on Tuesday, February 7, 2023

GlobeNewswire January 26, 2023

Medicenna (TSX:MDNA) obtains new patent for methods of treating cancer

Azuka Onwuka January 5, 2023

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs(TM) Programs with Issuance of U.S. Patent

GlobeNewswire January 5, 2023

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

GlobeNewswire November 10, 2022

Medicenna (TSX:MDNA) reports Q2 fiscal 2023 financial results & operational highlights

Jonathon Brown November 4, 2022

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

GlobeNewswire November 4, 2022

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire October 28, 2022

Medicenna to Announce Second Quarter Fiscal 2023 Financial Results and Operational Highlights on Friday, November 4, 2022

GlobeNewswire October 25, 2022

Medicenna Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

GlobeNewswire October 5, 2022

Medicenna Extends Period to Exercise Certain Warrants

GlobeNewswire September 30, 2022